BD (NYSE:BDX) today said it has received FDA 510(k) clearance for its PeritX peritoneal catheter system. Franklin Lakes, N.J.-based BD designed the catheter system to drain symptomatic, recurrent non-malignant ascites, which causes a build-up of fluid in the abdomen. Get the full story on our sister site, Medical Tubing + Extrusion.
BD
MedTech 100 roundup: Significant uptick for industry
The up-and-down nature of the medtech industry continues to carry through 2021, with a recent dip now followed by a rapid ascent. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week (June 11) at 109.63 points, producing a 2.5% rise from the 106.96-point mark set one […]
Inogen appoints BD veteran as chief medical officer
Inogen (NSDQ:INGN) this week announced that it has appointed Dr. Stanislav Glezer as EVP and chief medical officer, effective June 21. Glezer joins the Goleta, Calif.–based oxygen therapy technology company after a stint as worldwide VP of medical affairs for diabetes care at BD. Prior to BD, he served as chief medical officer at Adocia […]
BD surpasses 2 billion orders for COVID-19 injection devices
BD (NYSE:BDX) announced today that orders for its needles and syringes hit 2 billion amid global COVID-19 vaccination efforts. Franklin Lakes, N.J.-based BD’s latest milestone comes less than six months after the company surpassed 1 million orders for vaccine delivery devices in December 2020. The order total encompasses commitments to governments all over the globe, including the […]
BD is upping its game on cybersecurity
BD (NYSE: BDX) is touting that it is the first medical technology company authorized as a Common Vulnerability and Exposures (CVE) Numbering Authority by the CVE Program. BD officials say the authorization further boosts the company’s healthcare cybersecurity leadership. Get the full story on our sister site Medical Design & Outsourcing.
Barclays is bullish on medtech
A Barclays analysis projects that medtech might be on its way to a stretch of “outperformance” even in the wake of the COVID-19 pandemic. According to SeekingAlpha, the report cited eight reasons that make the investment bank bullish on the industry in the coming years, starting with what it calls “robust innovation.” On top of […]
MedTech 100 roundup: More growth ahead?
A turgid month for the medtech industry might be drifting into the past after the past week indicated a slight turnaround as summer nears. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week at 107.74 points, marking a 1.4% rise from the 106.22-point mark set one […]
BD to build $200M facility in Spain for pre-filled drug delivery device manufacturing
BD (NYSE:BDX) announced today that it will build a more than $200 million drug delivery device manufacturing facility in Spain. The approximately $201.5 million (€165 million) high-tech manufacturing facility in Zaragoza, Spain, is expected to create up to 600 jobs by 2030, according to a news release. Get the full story at our sister site, Drug […]
BD enrolls first patients in arteriovenous endovascular fistula post-market trial
BD (NYSE: BDX) recently announced that it has begun enrollment for its post-market surveillance study of its WavelinQ arteriovenous endovascular fistula device. The Connect-AV trial is a prospective, single-arm, open-label study that will follow WavelinQ EndoAVF system patients for 24 months. Its dual primary effectiveness endpoints are the percentage of subjects dialyzing with successful 2-needle cannulation […]
MedTech 100 roundup: Largest slide for industry in 2021
The medtech industry’s 2021 performance has been all over the place and the past weekend highlighted its topsy-turvy nature. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — had been on the rise since the beginning of April, with its mark of 112.25 on April 16 representing an all-time best and […]
BD to spin off its diabetes business, Q2 earnings beat The Street
BD (NYSE: BDX) announced today that it will spin off its Diabetes Care business as an independent, publicly traded company during the first half of 2022. The Diabetes Care business saw $1.1 billion in sales during BD’s fiscal year ended Sept. 30, 2020, nearly half outside the U.S. The business manufactures roughly 8 billion injection […]
